Rivaroxaban CAS:366789-02-8 Manufacturer Supplier

Rivaroxaban is a novel antithrombotic agent. It is a novel, oral, selective direct inhibitor of factor Xa developed by Bayer Healthcare. It has been approved by the EMEA and FDA for the prevention ofvenous thromboembolism in adult patients after total hip replacement or total kneereplacement surgery.

Products Details

Application and Effect

Rivaroxaban has the characteristics of high bioavailability, wide range of target diseases, stable dose-effect relationship, easy oral intake, and low bleeding risk.Rivaroxaban can also prevent and treat venous thrombosis. It is mainly used clinically to prevent deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients following hip and knee replacement surgery. It is also used to prevent patients with nonvalvular atrial fibrillation from cerebral apoplexy and noncentral nervous system embolism, and it can lower the recurrence risk of coronary syndromes.

Product Sample

Product Packing:

Additional Information:

Composition C19H18ClN3O5S
Assay 99%
Appearance White powder
CAS No. 366789-02-8
Packing 25KG
Shelf Life 2 years
Storage Store in cool and dry area
Certification ISO.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours